



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 39/395, C12Q 1/00, 1/68, C12N 9/00		A1	(11) International Publication Number: WO 00/54806 (43) International Publication Date: 21 September 2000 (21.09.00)
(21) International Application Number:	PCT/US00/06728		(72) Inventor; and
(22) International Filing Date:	15 March 2000 (15.03.00)		(75) Inventor/Applicant (<i>for US only</i>): CONOVER, Cheryl, A. [US/US]; 939 22nd Avenue SW, Rochester, MN 55902 (US).
(30) Priority Data:	60/124,541 15 March 1999 (15.03.99)	US	(74) Agents: GRAHAM, Monica McCormick et al.; Fish & Richardson P.C., P.A., 3300 Dain Rascher Plaza, 60 South Sixth Street, Minneapolis, MN 55402 (US).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application	US 60/124,541 (CON) Filed on 15 March 1999 (15.03.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(71) Applicant (<i>for all designated States except US</i>):	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street Southwest, Rochester, MN 55905 (US).		
(71)(72) Applicants and Inventors:	OVERGAARD, Michael, Toft [DK/DK]; Janus la Coursgade 12, st. th., DK-8000 Aarhus C (DK). OXVIG, Claus [DK/DK]; Soeskaanten 36, DK-8260 Viby J (DK).		
		Published	<i>With international search report.</i>

(54) Title: INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 PROTEASE

(57) Abstract

Methods for screening for altered focal proliferation states in non-pregnant patients, which include detecting levels of pregnancy-associated plasma protein-A (PAPP-A), are described. Methods for identifying agents that alter the protease activity of PAPP-A, and pharmaceutical compositions and medical devices that include such agents are also described.